Literature DB >> 24434359

Diagnosis and classification of psoriasis.

Smriti K Raychaudhuri1, Emanual Maverakis2, Siba P Raychaudhuri3.   

Abstract

Psoriasis is a chronic inflammatory multi organ disease with well characterized pathology occurring in the skin and often the joints. Although the disease has many characteristic and even pathognomonic features, no established diagnostic criteria exist for cutaneous psoriasis and there is no unified classification for the clinical spectrum of the disease. Prior approaches that have been taken to classify psoriasis include age of onset, severity of the disease, and morphologic evaluation. The latter has yielded plaque, guttate, pustular, and erythrodermic as subtypes of psoriasis. Unlike other autoimmune diseases, histopathological examination and blood tests are generally not valuable tools in making the diagnosis of psoriasis. However, on occasion, dermatopathologic evaluation may be helpful in confirming the diagnosis of psoriasis. Thus, in most cases the diagnosis of psoriasis is dependent primarily on pattern recognition that is morphologic evaluation of skin lesions and joints. Published by Elsevier B.V.

Entities:  

Keywords:  Clinical spectrum; Diagnosis; Diagnostic criteria; Psoriasis

Mesh:

Year:  2014        PMID: 24434359     DOI: 10.1016/j.autrev.2014.01.008

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  81 in total

1.  Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.

Authors:  Luisa Costa; Francesco Caso; Roberta Ramonda; Antonio Del Puente; Luca Cantarini; Md Abud Darda; Paolo Caso; Mariagrazia Lorenzin; Ugo Fiocco; Leonardo Punzi; Raffaele Scarpa
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 2.  Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis.

Authors:  Marwa R Al-Badri; Sami T Azar
Journal:  Ther Adv Endocrinol Metab       Date:  2014-04       Impact factor: 3.565

3.  Withasteroid B from D. metel L. regulates immune responses by modulating the JAK/STAT pathway and the IL-17+ RORγt+ /IL-10+ FoxP3+ ratio.

Authors:  Y Su; Q Wang; B Yang; L Wu; G Cheng; H Kuang
Journal:  Clin Exp Immunol       Date:  2017-08-04       Impact factor: 4.330

4.  DNA methylation-based subclassification of psoriasis in the Chinese Han population.

Authors:  Fusheng Zhou; Changbing Shen; Yi-Hsiang Hsu; Jing Gao; Jinfa Dou; Randy Ko; Xiaodong Zheng; Liangdan Sun; Yong Cui; Xuejun Zhang
Journal:  Front Med       Date:  2018-04-05       Impact factor: 4.592

Review 5.  Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides.

Authors:  Carolyn Jean Chua-Aguilera; Burkhard Möller; Nikhil Yawalkar
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

6.  Combination Therapy of Tacrolimus and Chinese Herb Medicated Bath in Children with Inverse Psoriasis.

Authors:  Min-Feng Wu; Su Li; Yong-Mei Qian; Xin Li; Yu Chen; Ruo-Yi Wei; Bin Li; Fu-Lun Li
Journal:  Chin J Integr Med       Date:  2017-09-15       Impact factor: 1.978

Review 7.  Immune responses and therapeutic options in psoriasis.

Authors:  Inna S Afonina; Elien Van Nuffel; Rudi Beyaert
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

8.  Does imiquimod pretreatment optimize 308-nm excimer laser (UVB) therapy in psoriasis patients?

Authors:  Joselin D Tacastacas; Patricia Oyetakin-White; David C Soler; Andrew Young; Sarah Groft; Kord Honda; Kevin D Cooper; Thomas S McCormick
Journal:  Photodermatol Photoimmunol Photomed       Date:  2017-04-20       Impact factor: 3.135

Review 9.  Autoimmunity in 2014.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

Review 10.  The Inflammatory Response in Psoriasis: a Comprehensive Review.

Authors:  Yaxiong Deng; Christopher Chang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.